Authors: Aså Ljungh, Jinggang Lan, and Naoko Yanagisawa.
Published: Microbial Ecology in Health and Disease 2002; Suppl 3.
The study uses both in vivo and in vitro methods.
Design:
Treatment: Lactobacillus strains were isolated from the deep colonic mucus layer of patients without gastrointestinal disease and screened for binding of porcine mucin. At autopsy, the colon was rinsed and biopsies were taken.
Where and when: Stockholm
Sample size: 74 patients.
Sample criteria: Patients admitted for a non-gastrointestinal disease were selected, provided they had not been treated with antibiotics during 3 months prior to sampling.
Analysed material:
Lactobacillus F19 and the other selected strains display characters that should enable them to survive passage to the large intestine in that they tolerate the acidic environment in the stomach (s. 5.).
The presented data show that Lactobacillus F19 has a documented ability to survive during passage in the GI tract and exerts multiple determinants for colonization and establishment, also expressed during conditions resembling those in the gut. Properties like fiber degradation, immunomodulatory effect and production of antioxidants make Lactobacillus F19 a strain, which is likely to exert further beneficial effects in the large intestine. (s. 6).
Det ser ut til at du er i Norge. Besøk vår norske nettside her www.supersynbiotics.no